Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
206 hedge funds and large institutions have $1.92B invested in Sage Therapeutics in 2022 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 56 increasing their positions, 74 reducing their positions, and 22 closing their positions.
232% more call options, than puts
Call options by funds: $22M | Put options by funds: $6.63M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
2% more funds holding
Funds holding: 201 → 206 (+5)
5% less capital invested
Capital invested by funds: $2.02B → $1.92B (-$96.5M)
2.03% less ownership
Funds ownership: 86.63% → 84.6% (-2%)
24% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$26.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.93M |
| 4 |
Morgan Stanley
New York
|
+$6.22M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.28M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.68M |
| 4 |
Goldman Sachs
New York
|
-$6.32M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.7M |
SAGE Hedge Fund Activity: Q4 2022 in Review
206 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2022, worth a combined $1.92B — down 4.8% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SAGE positions and 22 closed out — a net gain of 9 holders — while 56 added to existing stakes and 74 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $26.7M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $31.4M sold.
- 206 institutional investors held Sage Therapeutics (SAGE) as of Q4 2022, up from 201 in Q3 2022.
- Funds reported $1.92B of Sage Therapeutics stock for Q4 2022, down 4.8% quarter-over-quarter.
- 31 funds opened new Sage Therapeutics positions in Q4 2022 and 22 closed out, a net change of +9 holders.
- The largest Sage Therapeutics buyer in Q4 2022 was Camber Capital Management, an estimated $26.7M added.
- The largest Sage Therapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $31.4M sold.
Based on aggregated 13F filings for Q4 2022.